1.14.11.1: gamma-butyrobetaine dioxygenase
This is an abbreviated version!
For detailed information about gamma-butyrobetaine dioxygenase, go to the full flat file.
Word Map on EC 1.14.11.1
-
1.14.11.1
-
cardioprotective
-
carnitine-dependent
-
3-2,2,2-trimethylhydrazinium
-
mildronate
-
trimethyllysine
-
mid1
-
alpha4
-
medicine
-
d-carnitine
-
dihydrate
-
drug development
-
molecular biology
- 1.14.11.1
-
cardioprotective
-
carnitine-dependent
-
3-2,2,2-trimethylhydrazinium
- mildronate
- trimethyllysine
- mid1
-
alpha4
- medicine
- d-carnitine
- dihydrate
- drug development
- molecular biology
Reaction
Synonyms
4-trimethylaminobutyric acid dioxygenase, alpha-butyrobetaine hydroxylase, BBD, BBH, BBOX, BBOX1, Bu hydroxylase, butyrobetaine hydroxylase, gamma butyrobetaine hydroxylase, gamma-BBD, gamma-BBH, gamma-buryrobetaine dioxygenase, gamma-butyrobetaine dioxygenase, gamma-butyrobetaine hydroxylase, gamma-butyrobetaine hydroxylase 1, GBB hydroxylase, GBBH, hBBOX, oxygenase, gamma-butyrobetaine di-, psBBOX
ECTree
Advanced search results
Disease
Disease on EC 1.14.11.1 - gamma-butyrobetaine dioxygenase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Carcinogenesis
Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.
Colorectal Neoplasms
BBOX1-AS1 contributes to colorectal cancer progression by sponging hsa-miR-361-3p and targeting SH2B1.
Diabetic Nephropathies
Bioinformatics-based discovery of the urinary BBOX1 mRNA as a potential biomarker of diabetic kidney disease.
Heart Failure
Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.
Heart Failure
MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.
Hyperthyroidism
Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression.
Hypothyroidism
Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression.
Kidney Diseases
Bioinformatics-based discovery of the urinary BBOX1 mRNA as a potential biomarker of diabetic kidney disease.
Myocardial Infarction
Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.
Myocardial Infarction
MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.
Myocardial Infarction
Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size.
Neoplasms
Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.
Neoplasms
KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway.
Neoplasms
The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs.
Triple Negative Breast Neoplasms
BBOX1 promotes triple-negative breast cancer progression by controlling IP3R3 stability.
Triple Negative Breast Neoplasms
Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.
html completed